Related Experiment Video
Updated: Jun 9, 2025

A Neuronal Apoptosis Model induced by Spinal Cord Compression in Rat
Published on: June 29, 2021
Risk and clinical characteristics of spinal cord compression across different mucopolysaccharidosis types: A
Insung Kim1, Juyoung Sung1, Yoon Ji Ahn1
1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract:
In patients with mucopolysaccharidosis (MPS), the accumulation of glycosaminoglycans leads to various complications, including spinal cord compression (SCC). Although SCC is a well-known complication in MPS, data comparing its clinical features across different MPS types remain limited. This study aimed to investigate the timing, location, and underlying causes of SCC in MPS, as well as to compare the risk and clinical characteristics by MPS type. We conducted a retrospective cohort study, reviewing the medical records of 183 patients with all types of MPS who were followed at Samsung Medical Center from January 1995 to March 2024. The distribution of patients diagnosed with SCC by MPS type was 33.3% for type I, 10.5% for type II, 55.0% for type IV, and 100% for type VI. The median age at SCC diagnosis was 16.3 years. Compared to type II, the risk of SCC was higher for type I (2.4 times, 95% confidence interval [CI]: 0.9-6.2), type IV (3.5 times; 95% CI: 1.5-8.1), and type VI (4.5 times, 95% CI: 1.2-16.4). Enzyme replacement therapy did not reduce the risk of SCC (P = .70). Moreover, SCC most frequently occurred at the C0 to C4 and T11 to L2 spinal levels. In the cervical spine, ligament thickening, and skeletal deformities were the predominant causes, whereas in the thoracolumbar spine, kyphoscoliosis and intervertebral disc issues were the main contributors. Although there was no significant difference in the location of SCC (P = .99), the underlying causes varied significantly by MPS type (P < .001). SCC is a common complication in MPS, but its risk and pathophysiology vary by MPS type. Therefore, an individualized approach is needed for early detection and appropriate intervention.
Insights
Spinal cord compression (SCC) is common in mucopolysaccharidosis (MPS). Risk and causes of SCC vary by MPS type, necessitating individualized care for early detection and intervention.
Area of Science:
- Medical Genetics
- Neurology
- Orthopedics
Background:
- Mucopolysaccharidosis (MPS) involves glycosaminoglycan accumulation, leading to complications like spinal cord compression (SCC).
- Limited data exists comparing SCC clinical features across diverse MPS types.
- Understanding these variations is crucial for patient management.
Purpose of the Study:
- To investigate the timing, location, and causes of SCC in MPS patients.
- To compare the risk and clinical characteristics of SCC across different MPS types.
- To inform individualized approaches for SCC management in MPS.
Main Methods:
- Retrospective cohort study of 183 MPS patients (January 1995 - March 2024).
- Analysis of medical records to identify SCC diagnosis, timing, location, and causes.
- Statistical comparison of SCC risk and characteristics by MPS type.
Main Results:
- SCC occurred in 100% of MPS type VI patients, and frequently in types I and IV.
- Median age at SCC diagnosis was 16.3 years; risk was significantly higher in types I, IV, and VI compared to type II.
- Ligament thickening and skeletal deformities were common cervical causes, while kyphoscoliosis and disc issues affected the thoracolumbar spine.
Conclusions:
- Spinal cord compression is a frequent complication in mucopolysaccharidosis, with varying risk and underlying causes depending on the specific MPS type.
- Enzyme replacement therapy did not significantly alter SCC risk.
- An individualized approach to early detection and intervention is essential for managing SCC in MPS patients.
Related Concept Videos
Proteoglycans
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Lysosomal Hydrolases
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

